A citation-based method for searching scientific literature

M Santoro, F Carlomagno, A Romano, D P Bottaro, N A Dathan, M Grieco, A Fusco, G Vecchio, B Matoskova, M H Kraus. Science 1995
Times Cited: 704







List of co-cited articles
1207 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.
L M Mulligan, J B Kwok, C S Healey, M J Elsdon, C Eng, E Gardner, D R Love, S E Mole, J K Moore, L Papi. Nature 1993
34

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli,[...]. J Clin Oncol 2012
858
31

Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.
Samuel A Wells, Sylvia L Asa, Henning Dralle, Rossella Elisei, Douglas B Evans, Robert F Gagel, Nancy Lee, Andreas Machens, Jeffrey F Moley, Furio Pacini,[...]. Thyroid 2015
943
29

Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.
H Donis-Keller, S Dou, D Chi, K M Carlson, K Toshima, T C Lairmore, J R Howe, J F Moley, P Goodfellow, S A Wells. Hum Mol Genet 1993
27

The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.
C Eng, D Clayton, I Schuffenecker, G Lenoir, G Cote, R F Gagel, H K van Amstel, C J Lips, I Nishisho, S I Takai,[...]. JAMA 1996
775
27

A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma.
R M Hofstra, R M Landsvater, I Ceccherini, R P Stulp, T Stelwagen, Y Luo, B Pasini, J W Höppener, H K van Amstel, G Romeo. Nature 1994
945
27

Medullary thyroid cancer: management guidelines of the American Thyroid Association.
Richard T Kloos, Charis Eng, Douglas B Evans, Gary L Francis, Robert F Gagel, Hossein Gharib, Jeffrey F Moley, Furio Pacini, Matthew D Ringel, Martin Schlumberger,[...]. Thyroid 2009
812
26

Cabozantinib in progressive medullary thyroid cancer.
Rossella Elisei, Martin J Schlumberger, Stefan P Müller, Patrick Schöffski, Marcia S Brose, Manisha H Shah, Lisa Licitra, Barbara Jarzab, Viktor Medvedev, Michael C Kreissl,[...]. J Clin Oncol 2013
664
25


RET revisited: expanding the oncogenic portfolio.
Lois M Mulligan. Nat Rev Cancer 2014
297
22


KIF5B-RET fusions in lung adenocarcinoma.
Takashi Kohno, Hitoshi Ichikawa, Yasushi Totoki, Kazuki Yasuda, Masaki Hiramoto, Takao Nammo, Hiromi Sakamoto, Koji Tsuta, Koh Furuta, Yoko Shimada,[...]. Nat Med 2012
572
19

Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.
Francesca Carlomagno, Teresa Guida, Suresh Anaganti, Giancarlo Vecchio, Alfredo Fusco, Anderson J Ryan, Marc Billaud, Massimo Santoro. Oncogene 2004
184
18

RET, ROS1 and ALK fusions in lung cancer.
Kengo Takeuchi, Manabu Soda, Yuki Togashi, Ritsuro Suzuki, Seiji Sakata, Satoko Hatano, Reimi Asaka, Wakako Hamanaka, Hironori Ninomiya, Hirofumi Uehara,[...]. Nat Med 2012
901
17

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.
Rossella Elisei, Barbara Cosci, Cristina Romei, Valeria Bottici, Giulia Renzini, Eleonora Molinaro, Laura Agate, Agnese Vivaldi, Pinuccia Faviana, Fulvio Basolo,[...]. J Clin Endocrinol Metab 2008
323
17

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.
Doron Lipson, Marzia Capelletti, Roman Yelensky, Geoff Otto, Alex Parker, Mirna Jarosz, John A Curran, Sohail Balasubramanian, Troy Bloom, Kristina W Brennan,[...]. Nat Med 2012
616
16

Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret.
A Schuchardt, V D'Agati, L Larsson-Blomberg, F Costantini, V Pachnis. Nature 1994
16

Guidelines for diagnosis and therapy of MEN type 1 and type 2.
M L Brandi, R F Gagel, A Angeli, J P Bilezikian, P Beck-Peccoz, C Bordi, B Conte-Devolx, A Falchetti, R G Gheri, A Libroia,[...]. J Clin Endocrinol Metab 2001
16

Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC.
L M Mulligan, C Eng, C S Healey, D Clayton, J B Kwok, E Gardner, M A Ponder, A Frilling, C E Jackson, H Lehnert. Nat Genet 1994
546
16

Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.
Samuel A Wells, Furio Pacini, Bruce G Robinson, Massimo Santoro. J Clin Endocrinol Metab 2013
182
16

A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.
Cristina Romei, Raffaele Ciampi, Rossella Elisei. Nat Rev Endocrinol 2016
163
15

Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.
Vivek Subbiah, Justin F Gainor, Rami Rahal, Jason D Brubaker, Joseph L Kim, Michelle Maynard, Wei Hu, Qiongfang Cao, Michael P Sheets, Douglas Wilson,[...]. Cancer Discov 2018
201
15

RET tyrosine kinase signaling in development and cancer.
Elena Arighi, Maria Grazia Borrello, Hannu Sariola. Cytokine Growth Factor Rev 2005
306
14

RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients.
Shumei Kato, Vivek Subbiah, Erica Marchlik, Sheryl K Elkin, Jennifer L Carter, Razelle Kurzrock. Clin Cancer Res 2017
115
14

Selective RET kinase inhibition for patients with RET-altered cancers.
V Subbiah, V Velcheti, B B Tuch, K Ebata, N L Busaidy, M E Cabanillas, L J Wirth, S Stock, S Smith, V Lauriault,[...]. Ann Oncol 2018
191
14

RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation.
P Ballerini, S Struski, C Cresson, N Prade, S Toujani, C Deswarte, S Dobbelstein, A Petit, H Lapillonne, E-F Gautier,[...]. Leukemia 2012
65
20

ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.
Francesca Carlomagno, Donata Vitagliano, Teresa Guida, Fortunato Ciardiello, Giampaolo Tortora, Giancarlo Vecchio, Anderson J Ryan, Gabriella Fontanini, Alfredo Fusco, Massimo Santoro. Cancer Res 2002
481
13

PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas.
M Grieco, M Santoro, M T Berlingieri, R M Melillo, R Donghi, I Bongarzone, M A Pierotti, G Della Porta, A Fusco, G Vecchio. Cell 1990
821
13

Structure and chemical inhibition of the RET tyrosine kinase domain.
Phillip P Knowles, Judith Murray-Rust, Svend Kjaer, Rizaldy P Scott, Sarah Hanrahan, Massimo Santoro, Carlos F Ibáñez, Neil Q McDonald. J Biol Chem 2006
174
12

Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B.
K M Carlson, S Dou, D Chi, N Scavarda, K Toshima, C E Jackson, S A Wells, P J Goodfellow, H Donis-Keller. Proc Natl Acad Sci U S A 1994
519
12

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Samuel A Wells, Jessica E Gosnell, Robert F Gagel, Jeffrey Moley, David Pfister, Julie A Sosa, Michael Skinner, Annetta Krebs, James Vasselli, Martin Schlumberger. J Clin Oncol 2010
349
12

Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B.
Taranjit S Gujral, Vinay K Singh, Zongchao Jia, Lois M Mulligan. Cancer Res 2006
57
21

Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.
Nishant Agrawal, Yuchen Jiao, Mark Sausen, Rebecca Leary, Chetan Bettegowda, Nicholas J Roberts, Sheetal Bhan, Allen S Ho, Zubair Khan, Justin Bishop,[...]. J Clin Endocrinol Metab 2013
143
11

Structure and physiology of the RET receptor tyrosine kinase.
Carlos F Ibáñez. Cold Spring Harb Perspect Biol 2013
99
11

Multiple endocrine neoplasia type 2 RET protooncogene database: repository of MEN2-associated RET sequence variation and reference for genotype/phenotype correlations.
Rebecca L Margraf, David K Crockett, Patti M F Krautscheid, Ryan Seamons, Fernanda R O Calderon, Carl T Wittwer, Rong Mao. Hum Mutat 2009
99
11

Kinase fusions are frequent in Spitz tumours and spitzoid melanomas.
Thomas Wiesner, Jie He, Roman Yelensky, Rosaura Esteve-Puig, Thomas Botton, Iwei Yeh, Doron Lipson, Geoff Otto, Kristina Brennan, Rajmohan Murali,[...]. Nat Commun 2014
370
11

Oncogenic RET kinase domain mutations perturb the autophosphorylation trajectory by enhancing substrate presentation in trans.
Iván Plaza-Menacho, Karin Barnouin, Kerry Goodman, Rubén J Martínez-Torres, Annabel Borg, Judith Murray-Rust, Stephane Mouilleron, Phillip Knowles, Neil Q McDonald. Mol Cell 2014
45
24

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Benjamin J Solomon, Lavinia Tan, Jessica J Lin, Stephen Q Wong, Sebastian Hollizeck, Kevin Ebata, Brian B Tuch, Satoshi Yoda, Justin F Gainor, Lecia V Sequist,[...]. J Thorac Oncol 2020
95
11

RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor.
Ivan Plaza Menacho, Roelof Koster, Almer M van der Sloot, Wim J Quax, Jan Osinga, Tineke van der Sluis, Harry Hollema, Grzegorz M Burzynski, Oliver Gimm, Charles H C M Buys,[...]. Cancer Res 2005
66
15

Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation.
Sina Jasim, Anita K Ying, Steven G Waguespack, Thereasa A Rich, Elizabeth G Grubbs, Camilo Jimenez, Mimi I Hu, Gilbert Cote, Mouhammed Amir Habra. Thyroid 2011
44
22

Early malignant progression of hereditary medullary thyroid cancer.
Andreas Machens, Patricia Niccoli-Sire, Josef Hoegel, Karin Frank-Raue, Theo J van Vroonhoven, Hans-Dietrich Roeher, Robert A Wahl, Peter Lamesch, Friedhelm Raue, Bernard Conte-Devolx,[...]. N Engl J Med 2003
332
10

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
Martin J Schlumberger, Rossella Elisei, Lars Bastholt, Lori J Wirth, Renato G Martins, Laura D Locati, Barbara Jarzab, Furio Pacini, Chantal Daumerie, Jean-Pierre Droz,[...]. J Clin Oncol 2009
257
10

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.
Elaine T Lam, Matthew D Ringel, Richard T Kloos, Thomas W Prior, Michael V Knopp, Jiachao Liang, Steffen Sammet, Nathan C Hall, Paul E Wakely, Vasyl V Vasko,[...]. J Clin Oncol 2010
274
10

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.
F Michael Yakes, Jason Chen, Jenny Tan, Kyoko Yamaguchi, Yongchang Shi, Peiwen Yu, Fawn Qian, Felix Chu, Frauke Bentzien, Belinda Cancilla,[...]. Mol Cancer Ther 2011
802
10

Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
Luca Mologni, Sara Redaelli, Andrea Morandi, Ivan Plaza-Menacho, Carlo Gambacorti-Passerini. Mol Cell Endocrinol 2013
62
16

Central role of RET in thyroid cancer.
Massimo Santoro, Francesca Carlomagno. Cold Spring Harb Perspect Biol 2013
67
14

Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.
Qingling Huang, Valentina E Schneeberger, Noreen Luetteke, Chengliu Jin, Roha Afzal, Mikalai M Budzevich, Rikesh J Makanji, Gary V Martinez, Tao Shen, Lichao Zhao,[...]. Mol Cancer Ther 2016
52
19

Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
Alexander Drilon, Natasha Rekhtman, Maria Arcila, Lu Wang, Andy Ni, Melanie Albano, Martine Van Voorthuysen, Romel Somwar, Roger S Smith, Joseph Montecalvo,[...]. Lancet Oncol 2016
278
10

RET rearrangements are actionable alterations in breast cancer.
Bhavna S Paratala, Jon H Chung, Casey B Williams, Bahar Yilmazel, Whitney Petrosky, Kirstin Williams, Alexa B Schrock, Laurie M Gay, Ellen Lee, Sonia C Dolfi,[...]. Nat Commun 2018
53
18

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
Lori J Wirth, Eric Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, Jochen Lorch, Francis Worden, Marcia Brose, Jyoti Patel, Sophie Leboulleux,[...]. N Engl J Med 2020
181
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.